The global sepsis diagnostics market is estimated to grow at a significant CAGR during the forecast period. Sepsis is a major unmet medical need caused by a patient’s overwhelming and life-threatening immune response to infection and can lead to tissue damage, organ failure, and even death. Sepsis affects an estimated 20-30 million people globally every year. According to the Agency for Healthcare Research and Quality, sepsis is the most expensive condition treated in US hospitals, costing more than $20 billion and increasing annually on average by 11.9%.
A full report of Sepsis Diagnostics Market is available at: https://www.omrglobal.com/industry-reports/sepsis-diagnostics-market
The key players operating in the global sepsis diagnostics market is also driving the market growth. Players such as Abbott Laboratories, Inc., Becton, Dickinson & Co., Biomérieux SA, Bruker Corp., Danaher Corp., F. Hoffmann-La Roche Ltd., Luminex Corp., Qiagen NV, Siemens AG, Sysmex Corp., Thermo Fisher Scientific Inc., and Trinity Biotech Plc, among others are significantly contributing to the sepsis diagnostics industry growth by adopting various growth strategies. Product launches & developments, partnerships, agreements, and acquisitions are among some of the strategies adopted by the players to sustain in a competitive sepsis diagnostics market globally, during the forecast period.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/sepsis-diagnostics-market
In April 2019, the Scottish Government along with FEAT – The Fiona Elizabeth Agnew Trust, Sepsis Research center started a campaign across Scotland to create public awareness regarding signs and symptoms of sepsis.
In April 2019, the US FDA approved Beckman Coulter Inc., a Danaher Corp. company for its Early Sepsis Indicator. This indicator is a cellular biomarker designed and enables the identification of patients with sepsis or at high risk of developing the disease.
In August 2018, Sysmex Corp., a Japan-based company introduced its new HISCL Presepsin Assay Kit, for the detection of presepsin, the primary test parameter for bacterial sepsis. This kit aid in the early diagnosis of bacterial sepsis with higher accuracies in comparison with conventional biomarkers.
In May 2018, the US FDA approved T2 Biosystems, Inc., a US-based emerging medical examination solutions company for its T2Bacteria Panel. The novel developed panel is intended for the recognition of specific sepsis-causing bacterial pathogens in human whole blood specimens.
In March 2018, Biocartis Group NV, a molecular diagnostics company and Immunexpress Pty Ltd, a host response molecular diagnostic company, committed to improving clinical and economic outcomes for suspected sepsis patients, today announced that they have entered into a partnership agreement aimed at the development and commercialization of Immunexpress’ SeptiCypte test for use on Biocartis’ sample-to-result Idylla platform.
In October 2017, the US FDA approved bioMérieux SA for its BacT/ALERT VIRTUO fully automated blood culture system. Further, in January 2017, Bruker acquired InVivo Biotech Services GmbH, a Germany based company for the expansion of its microbiology assay menu for its MALDI Biotyper platform.
Global Sepsis Diagnostics Market – Segmentation
By Product Type
- Instruments
- Assays and Reagents
- Other Products
By Technology
- Molecular Diagnostics
- Immunoassay
- Others
By Pathogen
- Bacterial Sepsis Diagnostics
- Fungal Sepsis Diagnostics
- Others
